A 42-year-old woman from Mumbai presents with progressive menorrhagia and dysmenorrhea for the past 18 months. She reports soaking 8–10 pads per day during menses, lasting 7–8 days. On examination, the uterus is firm, enlarged (approximately 14 weeks size), and irregular. Transvaginal ultrasound reveals multiple intramural fibroids, the largest measuring 4 cm. Her hemoglobin is 9.2 g/dL. She desires fertility preservation. Which of the following is the most appropriate first-line medical management?

Explanation

## Medical Management of Symptomatic Fibroids with Fertility Desire **Key Point:** In a woman with symptomatic intramural fibroids desiring fertility, the first-line medical approach targets symptom control (menorrhagia, anemia) without compromising future conception or causing prolonged hormonal suppression. ### Why Tranexamic Acid is First-Line Here Tranexamic acid is an antifibrinolytic agent (plasminogen activator inhibitor) that reduces fibrinolysis and decreases menstrual blood loss by 40–50% in fibroid-related menorrhagia. It is: - **Non-hormonal** — does not interfere with ovulation or fertility - **Reversible** — no long-term effects on reproductive potential - **Effective** — reduces heavy menstrual bleeding in 60–70% of fibroid patients - **Safe** — minimal systemic side effects when used cyclically (during menses only) - **Guideline-supported** — recommended by RCOG (Green-top Guideline No. 44, 2016) and ACOG as first-line pharmacological therapy for menorrhagia in women wishing to preserve fertility **Note:** The WHO 2018 guidelines (not 2021) on menorrhagia support antifibrinolytics as first-line medical therapy for heavy menstrual bleeding. ### Why Not the Other Options? | Agent | Mechanism | Fertility Impact | Why Not First-Line Here | |-------|-----------|------------------|------------------------| | **LNG-IUD** | Local progestin; reduces endometrial proliferation | Preserves ovulation | Insertion is technically difficult and less effective in a significantly enlarged (14-week) uterus with multiple intramural fibroids; cavity distortion reduces efficacy and increases expulsion risk (RCOG/ACOG) | | **GnRH agonist** | Hypogonadotropic hypogonadism; induces fibroid shrinkage (20–40%) | Temporary amenorrhea; fertility returns post-cessation | Reserved for **preoperative** use (3–6 months) to shrink fibroids and reduce operative morbidity, or for rapid correction of severe anemia before surgery — NOT as standalone first-line long-term therapy due to cost, menopausal side effects, and bone loss (add-back therapy required beyond 6 months) | | **Hysterectomy** | Definitive removal of uterus | Eliminates fertility permanently | Absolutely contraindicated as first-line in a patient who desires fertility preservation | **Clinical Pearl (RCOG/ACOG):** GnRH agonists are a preoperative adjunct, not a primary medical treatment for fibroids. They do not cure fibroids — regrowth occurs within 3–6 months of cessation. Their role is to shrink fibroids before myomectomy or hysterectomy, or to correct anemia preoperatively. ### Algorithm for This Patient ``` 42-year-old with menorrhagia + fibroids + Hb 9.2 g/dL + desires fertility ↓ Iron supplementation (for anemia) + Tranexamic acid (for menorrhagia) ↓ Reassess at 3 months ↓ Poor response → Myomectomy (hysteroscopic/laparoscopic based on fibroid location) ``` **High-Yield for NEET PG:** Always establish fertility intentions before prescribing GnRH agonists or recommending hysterectomy. Tranexamic acid + iron supplementation is the safest, most fertility-friendly first-line combination for fibroid-related menorrhagia with anemia (Harrison's Principles of Internal Medicine, 21st ed.; RCOG Green-top Guideline No. 44).